Dashenlin Pharm Grp Co Ltd Net Asset Quality Index
Dashenlin Pharm Grp Co Ltd net asset quality index. Dashenlin Pharm Grp Co Ltd (603233) has a Net Asset Quality Index of 34.2% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥26.83 Billion minus total liabilities of CN¥17.65 Billion yields net assets of CN¥9.18 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See Dashenlin Pharm Grp Co Ltd (603233) shareholders funds for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Dashenlin Pharm Grp Co Ltd (2012–2025)
Net asset quality index of Dashenlin Pharm Grp Co Ltd from 2012 to 2025. This chart shows how Dashenlin Pharm Grp Co Ltd's Net Asset Quality Index has evolved across 14 annual periods from 2012 to 2025. As of March 2026, the index stands at 34.2%, representing net assets of CN¥9.18 Billion against total assets of CN¥26.83 Billion CNY. Check Dashenlin Pharm Grp Co Ltd strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Dashenlin Pharm Grp Co Ltd Net Asset Quality Index by Year (2012–2025)
Dashenlin Pharm Grp Co Ltd net asset quality index by year from 2012 to 2025. The table below presents the year-by-year Net Asset Quality Index for Dashenlin Pharm Grp Co Ltd from 2012 to 2025, covering 14 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see 603233 market cap overview.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 32.7% | CN¥8.66 Billion | CN¥26.49 Billion | CN¥17.83 Billion | ▲ +1.9 pp |
| 2024 | 30.8% | CN¥8.14 Billion | CN¥26.44 Billion | CN¥18.30 Billion | ▼ -2.1 pp |
| 2023 | 32.9% | CN¥7.93 Billion | CN¥24.12 Billion | CN¥16.19 Billion | ▼ 0.0 pp |
| 2022 | 32.9% | CN¥6.86 Billion | CN¥20.84 Billion | CN¥13.98 Billion | ▼ -1.3 pp |
| 2021 | 34.2% | CN¥5.94 Billion | CN¥17.34 Billion | CN¥11.40 Billion | ▼ -11.0 pp |
| 2020 | 45.2% | CN¥5.57 Billion | CN¥12.33 Billion | CN¥6.76 Billion | ▼ -4.8 pp |
| 2019 | 50.0% | CN¥4.33 Billion | CN¥8.67 Billion | CN¥4.34 Billion | ▲ +2.7 pp |
| 2018 | 47.2% | CN¥3.09 Billion | CN¥6.54 Billion | CN¥3.45 Billion | ▼ -0.9 pp |
| 2017 | 48.1% | CN¥2.80 Billion | CN¥5.82 Billion | CN¥3.02 Billion | ▲ +10.6 pp |
| 2016 | 37.5% | CN¥1.34 Billion | CN¥3.58 Billion | CN¥2.24 Billion | ▼ -0.9 pp |
| 2015 | 38.4% | CN¥1.02 Billion | CN¥2.66 Billion | CN¥1.64 Billion | ▲ +14.1 pp |
| 2014 | 24.3% | CN¥574.85 Million | CN¥2.37 Billion | CN¥1.79 Billion | ▼ -10.8 pp |
| 2013 | 35.1% | CN¥589.93 Million | CN¥1.68 Billion | CN¥1.09 Billion | ▼ -3.1 pp |
| 2012 | 38.2% | CN¥381.11 Million | CN¥996.51 Million | CN¥615.39 Million | — |